My question why nobody is really studying sulfasazine ? 

Economic

No important side effect

and the little studies that made after 3 months have good effect ...

So why? 

I'm using mesalazine ( a derivate ) for a a medical colits and after only 15 days not only my colitis better but a lot of hairs more (in eyebrwon, body, head)...i read that xelijanz begin to work in 3 months ...in mine personal case mesalazina(that is not effective like sulfasazine) work a lot of faster...of course i must see what happens in next month(my doctor said that also if my colitis now is good i must use metalazine minimum for other 3 months)....

here some link about sulfasazine

https://www.google.com.ec/?gfe_rd=cr&ei=5hugVr26L9eClAHA-4jgCQ#...

Views: 773

Reply to This

Replies to This Discussion

Another thing i read a lot of use xelijanz and make shot of cortison, noone tried to use sulfasazine and xelijanz? 

Can u pls message me your doctor details. Would appreciate it.

Yes Sulfasalazine have you read the link i posted about the results?

 A retrospective chart review performed by Ellis and colleagues[2] showed that 7 (23%) of 30 patients with alopecia areata treated with sulfasalazine for 3 months achieved cosmetically acceptable regrowth. Doses ranged from 1 to 4 g per day. Eleven patients discontinued the medication due to side effects, mainly gastrointestinal distress.

Aimee did you had side effects? whit Mesalazina to me fortunatly now all good and my colon very good respect to 15 days after...i have a big regrowth of hairs (and dark now) the only thing i'm making is mesalazina and  meditaion(30 minutes meditation of white light in all my body) so i'm almost sure the regrowth is for mesalazina ...can help meditation? mmm i'm making from 4 month and never so much hairs, the only difference now i'm making whit  white light before i made only respiration.

Here other study this time 6 months 

Clinical trial

In a recent open label, uncontrolled clinical trial, 26 patients with recalcitrant or severe alopecia areata (>40 percent scalp hair loss) were treated with sulfasalazine initially dosed at 500 mg bid for the first month, then 1 g bid for the second month, and finally with 1.5 g bid for a further three months.

Patients were grouped into three categories according to their response to treatment: no hair re-growth (<10 percent terminal hair), partial hair re-growth (10 percent to 90 percent terminal hair), and complete hair re-growth (90 percent to 100 percent terminal hair). If no re-growth was observed after six months of treatment, the patient was considered to be a non-responder and was dropped from the trial.

Twenty-two of 26 patients completed the study. Overall, results showed that 68.2 percent (15 of 22) of patients responded to therapy with 27.3 percent (six of 22 patients) and 40.9 percent (nine of 22 patients) demonstrating a complete hair re-growth and a partial hair re-growth, respectively.

Of the nine patients with partial hair growth response, five patients had 10-20 percent re-growth, two patients had 30-40 percent, one patient had 50 percent, and one patient had 60-70 percent re-growth. Results also showed that 45.5 percent (10 of 22 patients) with initially complete or partial remission suffered a partial or complete relapse either on maintenance treatment or after termination of therapy. Seven (31.8 percent) of patients had no hair re-growth and were dropped from the study.

“We saw that there was a remission in patients after the drug was either stopped or during the maintenance treatment phase. However, the relapse or partial relapse that occurs in these patients with sulfasalazine therapy is acceptable when looking at other treatment options," Dr. Aghaei says. "Topical, intralesional and especially oral corticosteroid therapy is the most common used approach and is the mainstay of therapy, however, though this approach may be effective in some patients, sulfasalazine is a good therapeutic option in lieu of the frequently encountered adverse events associated with corticosteroid therapy.”

Adverse events

The adverse events encountered in this small series of patients with sulfasalazine included gastrointestinal distress, rash, laboratory value abnormalities and headaches and was seen in 31.8 (seven of 22) percent of patients. These adverse events were all encountered within the first three months of treatment.

According to Dr. Aghaei, these side effects can be managed by lowering the dose of sulfasalazine or giving the patient a drug holiday.

Alopecia areata is a chronic disease and, therefore, a long-term therapeutic solution is needed that has less side effects than those typically seen with corticosteroid treatments. According to Dr. Aghaei, steroid sparing agents such as immunotherapy have a safer drug profile as well as a good tolerability in alopecia areata patients.

“It is clear that we need more effective therapies with minimal side effects for the treatment of alopecia areata. This study consisted of only a few patients, but I believe some inroads have been made in terms of finding alternative treatments for this disease. I think that dermatologists and dermatologic researchers could use this study as a platform to work from, and perform much larger controlled clinical trials with steroid-sparing drugs, perhaps directly comparing the therapeutic benefits of sulfasalazine to steroid and immunotherapy,” Dr. Aghaei says.

23% in 3 month in the xelian z study after 3 month if a remember are 50% ...to me xelijanz work but i'm really afraid to use a so strong drougs for a estetic problem and now all these people that are relapsing so having to use mesalazine for other 3-4 months i hope to be in the 20% :-)...

In this study of 6 month the 57% have had regrowth  but 30% only moderate 25% total ...the patientes were patientes whit alopecia that did not answer to steroidis or other drougs...so in 6 month the answer is good, of course no good like xelijanz BUT a sure droug and economic droug and work whit people that whit other drougs strong like steroids did not have answer...i would seee if i meet studies of a year or more cause in a lot of people xelianz begin to work after 8 or more months.

i begin to think it can be a answer to a lot of people here.

Una buona risposta al trattamento è stata ottenuta nel 25.6% dei pazienti, moderata nel 30.7% e scarsa o nessuna risposta nel 43.5%.

Aimee how much sulf you used...i use 500 500 and 500 mesalazina so 1, 5 gr the study of 6 months used 3 gr ...it's doble respect to how use 

My 17 year old daughter will try Sulfasalazin, we see the rheumatologyst at 1st Feb. and then start with this drug. 14 years ago I have been on Sulfasalazin for 2 years for RA  and had no side effects.  Hopefully it brings my daughters hair back.

I hope it helps your daugheter ...good lucky..

Thank you for your answer Aimee sorry to read about your sick...yes i read the dosis must be continue for long time and down very very slowly...

I would like to reply to this with my own experience. I had lost most of my hair after breast reduction surgery 4 and a half years ago. I lost so much that i just shaved the rest off, and I was in denial and clasping dearly to those last few pathetic hairs! A year ago i began taking MSM (methylsulfynlmethane)which is also a sulfa drug. I have grown most of my hair back, but it is still bare around what would call the "male pattern baldness" area. I will research this drug you are discussing more, because after this being the only thing that has given me hope, you also give me hope that i really HAVE been on the right track.

RSS

Disclaimer

Any mention of products and services on Alopecia World is for informational purposes only; it does not imply a recommendation or endorsement by Alopecia World. Nor should any statement or representation on this site be construed as professional, medical or expert advice, or as pre-screened or endorsed by Alopecia World. Alopecia World is not responsible or liable for any of the views, opinions or conduct, online or offline, of any user or member of Alopecia World.

© 2024   Created by Alopecia World.   Powered by

Badges  |  Report an Issue  |  Terms of Service